Lates News

According to the AI Fast News of Every Economy, Open Source Securities issued a research report on November 10th, giving DeYuan Pharmaceutical (920735.SH) a "buy" rating. The main reasons for the rating include: 1) Gliclazide sustained-release tablets have received registration certificate, and the first phase of raw material and formulation production complex base is about to be put into operation; 2) The eleventh batch of national centralized procurement adheres to the principles of "stability in clinical practice, quality assurance, prevention of internal turnover, and prevention of circle marking", comprehensively optimizing the rules. (Daily Economic News)